Anti-CD47 reference antibody (ligufalimab) is used as a tool in biopharmaceutical research and development, particularly in cancer immunotherapy. It binds to the CD47 protein, which is overexpressed on tumor cells and sends a "don't eat me" signal to immune cells, especially macrophages, enabling cancer cells to evade destruction. By blocking this signal, the antibody allows the immune system to recognize, phagocytose, and destroy cancer cells more effectively.

It is being investigated in clinical trials for various hematologic malignancies and solid tumors, often in combination with other antibodies or therapies to enhance anti-tumor activity. Additionally, it serves as a reference standard for developing commercial antibodies, enabling comparison of specificity, affinity, and target binding efficiency to ensure new products meet quality standards for laboratory and clinical applications.

Shows promise in promoting phagocytosis and activating adaptive immune responses against cancer.